| 1889-08-15 |
Eisai's founder, Toyoji Naito, is born on August 15 in Ito, a village in Fukui, central Japan. He is the sixth child and third son of Kikuji Naito and his wife, Fuji. |
| 1905 |
Toyoji leaves his village at age 15, heading west to find employment in Osaka. |
| 1906 |
Toyoji is employed at Winkel Shokai in nearby Kobe, a port city in Hyogo. Meanwhile, he takes night courses in foreign languages and bookkeeping. |
| 1909 |
Toyoji leaves Winkel Shokai on being drafted into the Japanese Imperial Guard. |
| 1911 |
After completing military service, Toyoji begins working in imported drugs at Thompson Trading Co., Ltd. in Kobe. |
| 1914 |
World War I begins. |
| 1915 |
Toyoji moves to Tokyo and begins working at Tanabe Motosaburo Store Co., Ltd. (now part of the Mitsubishi Tanabe Pharma Corporation). |
| 1917 |
Toyoji embarks on a seven-month business tour of India and Southeast Asia. |
| 1918 |
World War I ends. |
| 1921 |
Toyoji is involved in Tanabe Motosaburo Store Co., Ltd.'s development of aromatic castor oil : Castalol : and analgesic cream : Salomethyl : . |
| 1923 |
The Great Kanto Earthquake strikes. Tanabe Motosaburo Store Co., Ltd. falls on hard times, including when its main store in Tokyo burns down in the aftermath of the quake. |
| 1924 |
Tanabe Motosaburo Store Co., Ltd. acquires exclusive rights to market Japan's first anti-hypertensive drug, : Animasa : . A Japanese word Toyoji coins for 'high blood pressure' in his : Animasa : ad campaign enters the Japanese lexicon and remains a general medical term today. |
| 1933 |
A : Salomethyl : newspaper ad created by Toyoji wins Best Advertisement Award in the first award ceremony of Japan's Society for the Promotion of Newspaper Advertising. Tanabe Motosaburo Store Co., Ltd. launches vitamin A product : Haliva : (halibut liver oil tablets). |
| 1936 |
Sakuragaoka Laboratory Co., Ltd. is established as a limited partnership in Tokyo. |
| 1937 |
Toyoji travels abroad to observe pharmaceutical industries in Europe and the United States. |
| 1938 |
Sakuragaoka Laboratory Co., Ltd. launches vitamin E product : Juvela : through Tanabe Motosaburo Store Co., Ltd. Its chocolate-brown coating, 'hard outside, soft inside' pellets and stylish packaging garners much attention at the time. Juvela : becomes the laboratory's first success. Sakuragaoka Laboratory Co., Ltd. launches : Sampon : , Japan's first sanitary tampon, through Tanabe Motosaburo Store Co., Ltd. |
| 1939 |
World War II begins. |
| 1941 |
Nihon Eisai Co., Ltd., Eisai Co., Ltd.'s immediate predecessor, is established in Saitama, eastern Japan. |
| 1944 |
Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merge under the name Nihon Eisai Co., Ltd. |
| 1945 |
World War II ends. |
| 1950 |
Nihon Eisai Co., Ltd.'s contraceptive suppository : Sampoon : , researched and developed during Japan's postwar baby boom, receives official approval from the Japanese government. |
| 1950 |
Nihon Eisai Co., Ltd. launches cardiotonic : Neophyllin : in Japan. |
| 1952 |
Nihon Eisai Co., Ltd. launches high-dosage vitamin B1 and B2 product : Chocola BB Tablets : in Japan. |
| 1952 |
Nihon Eisai Co., Ltd. launches motion sickness remedy : Travelmin : in Japan. |
| 1955 |
The company changes its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd., as it is known today. |
| 1957 |
Eisai rolls out its first three-year mid-term plan. |
| 1957 |
Eisai's Head Office building is completed in Tokyo. |
| 1961 |
Eisai opens its Taipei Office (now part of Eisai Taiwan Inc.), the company's first overseas branch, in Taiwan. |
| 1961 |
Eisai is publicly listed in the First Section of both the Tokyo and Osaka Stock Exchanges. |
| 1961 |
Gastrointestinal remedies : Saclon : and : Saclon Tablets : , recognizable for their distinct green hue even today, are launched in Japan. |
| 1964 |
Toyoji Naito receives the Japan Marketing Award, which recognizes people who have made a significant contribution to marketing and advertising in Japan. |
| 1966 |
The Kawashima Plant is completed in Gifu, central Japan. |
| 1966 |
Kawashima Plant opening ceremony. |
| 1966 |
Founder Toyoji Naito is appointed as chairman and Yuji Naito as company president. |
| 1966 |
A three-tier representative director system is introduced: Chairman Toyoji Naito, President Yuji Naito, and Executive Vice President Tatsuo Naito. |
| 1969 |
Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan. |
| 1970 |
PT Eisai Indonesia is established as a pharmaceutical manufacturing and sales subsidiary in Indonesia. |
| 1970 |
Toyoji Naito resigns as representative director and chairman to assume director and honorary chairman roles. |
| 1971 |
Toyoji opens the Naito Museum of Pharmaceutical Science and Industry, Japan's first pharmaceutical museum, in Gifu. |
| 1974 |
Eisai (Malaysia) Sdn. Bhd. is established as a pharmaceutical sales subsidiary in Malaysia. |
| 1974 |
Hi-Eisai Pharmaceutical Inc. is established as a pharmaceutical sales subsidiary in the Philippines. |
| 1974 |
Metabolic cardiotonic : Neuquinon : is launched in Japan. |
| 1977 |
Naturally derived vitamin E product : Juvelux : is launched in Japan. |
| 1978 |
Eisai's founder Toyoji Naito passes away at age 89. |
| 1978 |
Peripheral neuropathy treatment : Methycobal : is launched in Japan. |
| 1979 |
Eisai Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore. |
| 1981 |
Eisai U.S.A. Inc. is established as a chemical and pharmaceutical machinery sales subsidiary in California, the United States. |
| 1981 |
The Misato Plant commences pharmaceutical manufacturing in Saitama. |
| 1981 |
Large-scale automated sugar-coating equipment (pan diameter of up to 170 cm) at the Misato Plant |
| 1982 |
The Tsukuba Research Laboratories open in Ibaraki, eastern Japan. |
| 1983 |
Eisai Chemical Co., Ltd. (now Eisai's Kashima Plant) is established in Ibaraki to manufacture active pharmaceutical ingredients (APIs). |
| 1984 |
Gastritis and gastric ulcer treatment : Selbex : is launched in Japan. |
| 1987 |
Eisai has supported of the Health and Medical Care Contributions Awards, which are presented to healthcare professionals who have contributed significantly to improving access to healthcare in difficult-to-reach areas from 1987 to 2015. |
| 1987 |
Eisai rolls out its first five-year mid-term plan. |
| 1987 |
Eisai Research Institute of Boston, Inc. (now the Boston Research Institute) is established as a discovery research subsidiary in Massachusetts, the United States. |
| 1988 |
President Yuji Naito steps down from office and assumes the role of chairman; Vice President Haruo Naito is appointed president of Eisai. |
| 1988 |
Eisai America, Inc. is established as a clinical research subsidiary in New Jersey, the United States. |
| 1988 |
Eisai Europe Ltd. is established as a clinical research subsidiary in London, the United Kingdom. |
| 1989 |
Eisai Machinery GmbH is established as a pharmaceutical machinery sales subsidiary in Cologne, former West Germany. |
| 1989 |
Eisai (Thailand) Marketing Co., Ltd. is established as a pharmaceutical sales subsidiary in Bangkok, Thailand. |
| 1990 |
Haruo Naito announces Eisai's “Commitment to Innovation.” |
| 1990 |
Eisai London Research Laboratories, Ltd. is established as a discovery research subsidiary attached to University College London in the United Kingdom. |
| 1991 |
Eisai Hong Kong Co., Ltd. is established as a pharmaceutical sales subsidiary in Hong Kong. |
| 1991 |
The Beijing Representative Office is established in Beijing, China. |
| 1991 |
Shenyang Eisai Pharmaceutical Co., Ltd. is established as a Chinese–foreign contractual joint venture in pharmaceutical manufacturing and sales in Shenyang, China. |
| 1991 |
Eisai celebrates its 50th anniversary. |
| 1992 |
Eisai adopts its current Corporate Mission and Corporate Objective. |
| 1992 |
Eisai Corporation of North America is established as a holding company in New Jersey, the United States. |
| 1992 |
Eisai London Research Laboratories, Ltd. is completed in the United Kingdom to form an Eisai Group multipolar R&D network spanning Japan, America and Europe. |
| 1993 |
Eisai London Research Laboratories opening ceremony in 1993 attended by the United Kingdom's Princess Royal, Princess Anne. |
| 1995 |
Eisai Inc. is established as a pharmaceutical sales subsidiary in New Jersey, the United States. |
| 1995 |
Eisai Ltd. is established as a pharmaceutical sales subsidiary in London, the United Kingdom. |
| 1995 |
Eisai Deutschland GmbH is established as a pharmaceutical sales subsidiary in Frankfurt, Germany. |
| 1996 |
Eisai S.A. is established as a pharmaceutical sales subsidiary in Paris, France. |
| 1996 |
Eisai Suzhou Pharmaceutical Co., Ltd. is established as a pharmaceutical manufacturing and sales subsidiary in Jiangsu, China. |
| 1996 |
Elmed Eisai Co., Ltd. is established as a generic drug sales subsidiary in Tokyo. |
| 1997 |
KAN Research Institute, Inc. (now Kobe Research Laboratories, in Hyogo) is established as a life science exploratory research subsidiary in Osaka, Japan. |
| 1997 |
Eisai Korea Inc. is established as a pharmaceutical sales subsidiary in Seoul, South Korea. |
| 1997 |
Eisai Inc. North Carolina Plant is established as a pharmaceutical manufacturing and formulation R&D facility at Research Triangle Park in North Carolina, the United States. |
| 1997 |
Anti-Alzheimer's agent Aricept is launched in the United States, the United Kingdom and Germany. |
| 1997 |
Proton-pump inhibitor Pariet is launched in Japan. |
| 1998 |
Aricept is launched in France. |
| 1998 |
Pariet is launched in Germany and the United Kingdom. |
| 1999 |
Pariet is launched under the brand name AcipHex in the United States. |
| 1999 |
Aricept is launched in Japan. |
| 2001 |
Eisai Farmacéutica S.A. is established as a pharmaceutical sales and marketing subsidiary in Madrid, Spain. |
| 2002 |
Eisai Medical Research Inc. is established as a clinical research subsidiary in New Jersey, the United States. |
| 2004 |
Eisai adopts the “Company with Committees” system. |
| 2004 |
Eisai Europe Ltd. is established as a European regional headquarters (holding company) in London, the United Kingdom. |
| 2004 |
Eisai Pharmaceuticals India Pvt. Ltd. is established as a pharmaceutical sales subsidiary in Mumbai, India. |
| 2005 |
Eisai S.r.l is established as a pharmaceutical sales subsidiary in Milan, Italy. |
| 2005 |
Eisai Pharma AG is established as a pharmaceutical sales subsidiary in Zurich, Switzerland. |
| 2005 |
The Corporate Mission is added to the Eisai Articles of Incorporation. |
| 2005 |
Eisai AB is established as a pharmaceutical sales subsidiary in Stockholm, Sweden. |
| 2005 |
Honorary chairman and Eisai's second president Yuji Naito passes away at age 85. |
| 2006 |
Eisai Australia Pty. Ltd. is established as a pharmaceutical sales subsidiary in Sydney, Australia. |
| 2006 |
Eisai rolls out its fifth mid-term plan, the “Dramatic Leap Plan.” |
| 2006 |
Eisai (Singapore) Pte. Ltd. is established as a pharmaceutical sales subsidiary in Singapore. |
| 2006 |
Eisai Clinical Research Singapore Pte. Ltd. is established as a clinical research subsidiary in Singapore. |
| 2006 |
Eisai acquires four anticancer agents from Ligand Pharmaceuticals Inc. in the United States. |
| 2006 |
EF-Eisai Farmacêutica, Unipessoal Lda. is established as a pharmaceutical sales subsidiary in Lisbon, Portugal. |
| 2007 |
Eisai Manufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom. |
| 2007 |
Eisai acquires Morphotek Inc., a bioventure specialized in antibody research, in the United States. |
| 2007 |
Eisai Pharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India. |
| 2007 |
Eisai SA/NV is established as a pharmaceutical sales subsidiary in Brussels, Belgium. |
| 2008 |
Eisai acquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States. |
| 2008 |
Eisai Machinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery. |
| 2008 |
Rheumatoid arthritis treatment Humira is launched in Japan. |
| 2009 |
Eisai GesmbH is established as a pharmaceutical sales subsidiary in Vienna, Austria. |
| 2009 |
The European Knowledge Centre (now EMEA Knowledge Centre) opens as a European strategic base in Hertfordshire, the United Kingdom. |
| 2009 |
The Eisai Product Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D. |
| 2009 |
Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations. |
| 2009 |
The Eisai Knowledge Centre, India opens as a manufacturing and process research base in Vizag, India. |
| 2010 |
The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award. |
| 2010 |
Eisai Limited is established as a pharmaceutical sales subsidiary in Ontario, Canada. |
| 2010 |
Production headquarters transforms to a global “Eisai Demand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing. |
| 2010 |
Eisai (Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China. |
| 2010 |
Anticancer agent : Halaven : is launched in the United States. |
| 2010 |
Eisai signs a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge. |
| 2010 |
H3 Biomedicine Inc. is established as a research subsidiary in the United States. |
| 2011 |
The Great East Japan Earthquake strikes. |
| 2011 |
Eisai rolls out its sixth mid-term plan, “HAYABUSA.” |
| 2011 |
Eisai Participações Ltda. is established as a pharmaceutical sales subsidiary in São Paulo, Brazil. |
| 2011 |
Halaven : is launched in Europe and Japan. |
| 2011 |
Eisai Laboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico. |
| 2012 |
Eisai signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020. |
| 2012 |
Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ). |
| 2012 |
Antiepileptic agent : Fycompa : is launched in Europe. |
| 2013 |
Limited Liability Company Eisai is established as a pharmaceutical sales subsidiary in Moscow, Russia. |
| 2013 |
Eisai co-establishes the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public–private partnership to advance development of new health technologies for the developing world. |
| 2013 |
Eisai initiates free of charge provision of diethylcarbamine tablets produced at its Vizag plant in India to WHO for use in the treatment of lymphatic filariasis. |
| 2014 |
Fycompa : is launched in the United States. |
| 2014 |
Eisai China Holdings Ltd. is established as a holding company in Suzhou, China. |
| 2015 |
Anticancer agent : Lenvima : is launched in the United States, Japan and Europe. |
| 2015 |
Eisai completes acquisition of Chinese generic pharmaceutical company Liaoning Tianyi Biological Pharmaceutical Co., Ltd. (new trading name: Eisai (Liaoning) Pharmaceutical Co., Ltd.) |
| 2016 |
Eisai rolls out its seventh mid-term plan “EWAY2025.” |
| 2016 |
EA Pharma Co., Ltd. is established as a gastrointestinal specialty pharmaceutical company. |
| 2016 |
Fycompa : is launched in Japan. |
| 2017 |
Eisai joins global partnership to address non-communicable diseases. |
| 2017 |
Eisai pledges continued support for lymphatic filariasis elimination. |
| 2017 |
Eisai commits funding to the 2nd phase of Global Health Innovative Technology Fund activities. |
| 2017 |
Collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments including aducanumab expanded. |
| 2018 |
Eisai agrees upon a strategic collaboration for : Lenvima : with Merck & Co., Inc., Kenilworth, N.J., U.S.A. |
| 2018 |
New Suzhou plant in China commences full-scale operation. |
| 2018 |
Lenvima : (hepatocellular carcinoma) is launched in China. |
| 2019 |
Eisai Center for Genetics Guided Dementia Discovery (G2D2) in Massachusetts, U.S., commences full-scale operation. |
| 2019 |
G2D2 Parkinson’s disease treatment Equfina is launched in Japan. |
| 2019 |
Fycompa and Halaven are launched in China. |
| 2020 |
NouKNOW (pronounced “NOH-NOH”), a new tool for self-assessment of brain performance (brain health) is launched in Japan. |
| 2020 |
DAYVIGO (insomnia treatment) is launched in the United States and Japan. |
| 2020 |
Eisai Vietnam Co., Ltd. is established as a pharmaceutical sales subsidiary in Ho Chi Minh City, Vietnam. |
| 2020 |
Unlimit Health Limited is established in Shanghai, China. |
| 2021 |
Eisai rolls out its eighth medium-term business plan 'EWAY Future ＆Beyond'. |
| 2021 |
Alzheimer’s disease treatment ADUHELM is granted accelerated approval and launched in the United States. |
| 2021 |
Eisai enters into a global strategic collaboration agreement with Bristol-Myers Squibb Company for MORAb-202. |
| 2021 |
Eisai Israel Ltd. is established as a pharmaceutical sales subsidiary in Tel Aviv, Israel. |
| 2021 |
Eisai celebrates its 80th anniversary. |
| 2022 |
Eisai and Biogen amend collaboration agreements on ADUHELM. |
| 2022 |
Eisai makes Arteryex Inc., a company that plans and develops software, its subsidiary. |
| 2022 |
Eisai Pharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa. |
| 2022 |
Eisai signs the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases. |
| 2022 |
Deep Human Biology Learning (DHBL), a new R&D organization, commences full-scale operation. |
| 2023 |
Alzheimer’s disease treatment LEQEMBI is granted accelerated approval and launched in the United States. |
| 2023 |
Eisai commits funding to the 3rd phase of Global Health Innovative Technology Fund. |
| 2023 |
LEQEMBI is granted traditional approval by the FDA. |
| 2023 |
Theoria technologies Co., Ltd. is established as a digital business company in Tokyo, Japan. |
| 2023 |
LEQEMBI is launched in Japan. |
